Skip to main content
Erschienen in: CardioVascular and Interventional Radiology 1/2017

03.11.2016 | Clinical Investigation

CT Perfusion for Early Response Evaluation of Radiofrequency Ablation of Focal Liver Lesions: First Experience

verfasst von: Herman P. Marquez, Gilbert Puippe, Rishi Philip Mathew, Hatem Alkadhi, Thomas Pfammatter, Michael A. Fischer

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the value of perfusion CT (P-CT) for early assessment of treatment response in patients undergoing radiofrequency ablation (RFA) of focal liver lesions.

Methods and Materials

20 consecutive patients (14 men; mean age 64 ± 14) undergoing P-CT within 24 h after RFA of liver metastases (n = 10) or HCC (n = 10) were retrospectively included. Two readers determined arterial liver perfusion (ALP, mL/min/100 mL), portal liver perfusion (PLP, mL/min/100 mL), and hepatic perfusion index (HPI, %) in all post-RFA lesions by placing a volume of interest in the necrotic central (CZ), the transition (TZ), and the surrounding parenchymal (PZ) zone. Patients were classified into complete responders (no residual tumor) and incomplete responders (residual/progressive tumor) using imaging follow-up with contrast-enhanced CT or MRI after a mean of 57 ± 30 days. Prediction of treatment response was evaluated using the area under the curve (AUC) from receiver operating characteristic analysis.

Results

Mean ALP/PLP/HPI of both readers were 4.8/15.4/61.2 for the CZ, 9.9/16.8/66.3 for the TZ and 20.7/29.0/61.8 for the PZ. Interreader agreement of HPI was fair for the CZ (intraclass coefficient 0.713), good for the TZ (0.813), and excellent for the PZ (0.920). For both readers, there were significant differences in HPI of the CZ and TZ between responders and nonresponders (both, P < 0.05). HPI of the TZ showed the highest AUC (0.911) for prediction of residual tumor, suggesting a cut-off value of 76 %.

Conclusion

Increased HPI of the transition zone assessed with P-CT after RFA might serve as an early quantitative biomarker for residual tumor in patients with focal liver lesions.
Literatur
1.
Zurück zum Zitat European Association For The Study Of The. L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. doi:10.1016/j.jhep.2011.12.001.CrossRef European Association For The Study Of The. L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. doi:10.​1016/​j.​jhep.​2011.​12.​001.CrossRef
4.
5.
Zurück zum Zitat Montorsi M, Santambrogio R, Bianchi P, Donadon M, Moroni E, Spinelli A et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg. 2005;9(1):62–7; discussion 7–8. doi:10.1016/j.gassur.2004.10.003. Montorsi M, Santambrogio R, Bianchi P, Donadon M, Moroni E, Spinelli A et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg. 2005;9(1):62–7; discussion 7–8. doi:10.​1016/​j.​gassur.​2004.​10.​003.
8.
Zurück zum Zitat Kierans AS, Elazzazi M, Braga L, Leonardou P, Gerber DA, Burke C, et al. Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol. 2010;194(2):523–9. doi:10.2214/AJR.09.2621.CrossRefPubMed Kierans AS, Elazzazi M, Braga L, Leonardou P, Gerber DA, Burke C, et al. Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol. 2010;194(2):523–9. doi:10.​2214/​AJR.​09.​2621.CrossRefPubMed
9.
Zurück zum Zitat Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging after percutaneous radiofrequency ablation of hepatic tumors: part 2, abnormal findings. AJR Am J Roentgenol. 2013;200(1):194–204. doi:10.2214/AJR.12.8479.CrossRefPubMed Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging after percutaneous radiofrequency ablation of hepatic tumors: part 2, abnormal findings. AJR Am J Roentgenol. 2013;200(1):194–204. doi:10.​2214/​AJR.​12.​8479.CrossRefPubMed
10.
Zurück zum Zitat Attenberger UI, Morelli J, Budjan J, Henzler T, Sourbron S, Bock M, et al. Fifty years of technological innovation: potential and limitations of current technologies in abdominal magnetic resonance imaging and computed tomography. Investig Radiol. 2015;50(9):584–93. doi:10.1097/RLI.0000000000000173.CrossRef Attenberger UI, Morelli J, Budjan J, Henzler T, Sourbron S, Bock M, et al. Fifty years of technological innovation: potential and limitations of current technologies in abdominal magnetic resonance imaging and computed tomography. Investig Radiol. 2015;50(9):584–93. doi:10.​1097/​RLI.​0000000000000173​.CrossRef
11.
Zurück zum Zitat Fischer MA, Kartalis N, Grigoriadis A, Loizou L, Stal P, Leidner B, et al. Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. Eur Radiol. 2015;. doi:10.1007/s00330-015-3732-1.PubMedCentral Fischer MA, Kartalis N, Grigoriadis A, Loizou L, Stal P, Leidner B, et al. Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. Eur Radiol. 2015;. doi:10.​1007/​s00330-015-3732-1.PubMedCentral
12.
13.
Zurück zum Zitat Morsbach F, Sah BR, Spring L, Puippe G, Gordic S, Seifert B, et al. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol. 2014;24(7):1455–65. doi:10.1007/s00330-014-3180-3.CrossRefPubMed Morsbach F, Sah BR, Spring L, Puippe G, Gordic S, Seifert B, et al. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol. 2014;24(7):1455–65. doi:10.​1007/​s00330-014-3180-3.CrossRefPubMed
14.
15.
Zurück zum Zitat Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, et al. Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World J Gastroenterol. 2010;16(47):5993–6000.PubMedPubMedCentral Ippolito D, Bonaffini PA, Ratti L, Antolini L, Corso R, Fazio F, et al. Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World J Gastroenterol. 2010;16(47):5993–6000.PubMedPubMedCentral
16.
Zurück zum Zitat Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol. 2008;191(1):133–9. doi:10.2214/AJR.07.2848.CrossRefPubMed Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol. 2008;191(1):133–9. doi:10.​2214/​AJR.​07.​2848.CrossRefPubMed
17.
Zurück zum Zitat Ippolito D, Fior D, Bonaffini PA, Capraro C, Leni D, Corso R, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol. 2014;83(9):1665–71. doi:10.1016/j.ejrad.2014.05.040.CrossRefPubMed Ippolito D, Fior D, Bonaffini PA, Capraro C, Leni D, Corso R, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol. 2014;83(9):1665–71. doi:10.​1016/​j.​ejrad.​2014.​05.​040.CrossRefPubMed
19.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35(3):421–30.CrossRefPubMed Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35(3):421–30.CrossRefPubMed
20.
Zurück zum Zitat Goetti R, Leschka S, Desbiolles L, Klotz E, Samaras P, von Boehmer L, et al. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Investig Radiol. 2010;45(7):419–26. doi:10.1097/RLI.0b013e3181e1937b. Goetti R, Leschka S, Desbiolles L, Klotz E, Samaras P, von Boehmer L, et al. Quantitative computed tomography liver perfusion imaging using dynamic spiral scanning with variable pitch: feasibility and initial results in patients with cancer metastases. Investig Radiol. 2010;45(7):419–26. doi:10.​1097/​RLI.​0b013e3181e1937b​.
21.
Zurück zum Zitat Fischer MA, Brehmer K, Svensson A, Aspelin P, Brismar TB. Renal versus splenic maximum slope based perfusion CT modelling in patients with portal-hypertension. Eur Radiol. 2016;. doi:10.1007/s00330-016-4277-7. Fischer MA, Brehmer K, Svensson A, Aspelin P, Brismar TB. Renal versus splenic maximum slope based perfusion CT modelling in patients with portal-hypertension. Eur Radiol. 2016;. doi:10.​1007/​s00330-016-4277-7.
22.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed
24.
Zurück zum Zitat Preda L, Calloni SF, Moscatelli ME, Cossu Rocca M, Bellomi M. Role of CT perfusion in monitoring and prediction of response to therapy of head and neck squamous cell carcinoma. Biomed Res Int. 2014;2014:917150. doi:10.1155/2014/917150. Preda L, Calloni SF, Moscatelli ME, Cossu Rocca M, Bellomi M. Role of CT perfusion in monitoring and prediction of response to therapy of head and neck squamous cell carcinoma. Biomed Res Int. 2014;2014:917150. doi:10.​1155/​2014/​917150.
25.
Zurück zum Zitat Chen G, Ma DQ, He W, Zhang BF, Zhao LQ. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2008;14(37):5738–43.CrossRefPubMedPubMedCentral Chen G, Ma DQ, He W, Zhang BF, Zhao LQ. Computed tomography perfusion in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2008;14(37):5738–43.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13(2):120–5. doi:10.1634/theoncologist.2007-0174.CrossRefPubMed Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13(2):120–5. doi:10.​1634/​theoncologist.​2007-0174.CrossRefPubMed
28.
Zurück zum Zitat Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015;25(7):1993–2003. doi:10.1007/s00330-015-3595-5.CrossRefPubMedPubMedCentral Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, et al. Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015;25(7):1993–2003. doi:10.​1007/​s00330-015-3595-5.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R. 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med. 2015;120(8):695–704. doi:10.1007/s11547-015-0514-4.CrossRefPubMed Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R. 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med. 2015;120(8):695–704. doi:10.​1007/​s11547-015-0514-4.CrossRefPubMed
31.
Zurück zum Zitat Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221(2):447–54. doi:10.1148/radiol.2212010446.CrossRefPubMed Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology. 2001;221(2):447–54. doi:10.​1148/​radiol.​2212010446.CrossRefPubMed
32.
Zurück zum Zitat Ippolito D, Casiraghi AS, Talei Franzesi C, Bonaffini PA, Fior D, Sironi S. Intraobserver and interobserver agreement in the evaluation of tumor vascularization with computed tomography perfusion in cirrhotic patients with hepatocellular carcinoma. J Comput Assist Tomogr. 2016;40(1):152–9. doi:10.1097/RCT.0000000000000331.CrossRefPubMed Ippolito D, Casiraghi AS, Talei Franzesi C, Bonaffini PA, Fior D, Sironi S. Intraobserver and interobserver agreement in the evaluation of tumor vascularization with computed tomography perfusion in cirrhotic patients with hepatocellular carcinoma. J Comput Assist Tomogr. 2016;40(1):152–9. doi:10.​1097/​RCT.​0000000000000331​.CrossRefPubMed
Metadaten
Titel
CT Perfusion for Early Response Evaluation of Radiofrequency Ablation of Focal Liver Lesions: First Experience
verfasst von
Herman P. Marquez
Gilbert Puippe
Rishi Philip Mathew
Hatem Alkadhi
Thomas Pfammatter
Michael A. Fischer
Publikationsdatum
03.11.2016
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 1/2017
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-016-1444-9

Weitere Artikel der Ausgabe 1/2017

CardioVascular and Interventional Radiology 1/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.